Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis PDF Download

Author:
Publisher: World Health Organization
ISBN: 9240026436
Category : Medical
Languages : en
Pages : 88

View

Book Description

Author: Prashant Kesharwani
Publisher: Academic Press
ISBN: 0128184817
Category : Medical
Languages : en
Pages : 434

View

Book Description
Drug Discovery Targeting Drug-Resistant Bacteria explores the status and possible future of developments in fighting drug-resistant bacteria. The book covers the majority of microbial diseases and the drugs targeting them. In addition, it discusses the potential targeting strategies and innovative approaches to address drug resistance. It brings together academic and industrial experts working on discovering and developing drugs targeting drug-resistant (DR) bacterial pathogens. New drugs active against drug-resistant pathogens are discussed, along with new strategies being used to discover molecules acting via new modes of action. In addition, alternative therapies such as peptides and phages are included. Pharmaceutical scientists, microbiologists, medical professionals, pathologists, researchers in the field of drug discovery, infectious diseases and microbial drug discovery both in academia and in industrial settings will find this book helpful. Written by scientists with extensive industrial experience in drug discovery Provides a balanced view of the field, including its challenges and future directions Includes a special chapter on the identification and development of drugs against pathogens which exhibit the potential to be used as weapons of war

Author: Thomas J. Dougherty
Publisher: Springer Science & Business Media
ISBN: 1461414008
Category : Medical
Languages : en
Pages : 1119

View

Book Description
This volume covers all aspects of the antibiotic discovery and development process through Phase II/III. The contributors, a group of highly experienced individuals in both academics and industry, include chapters on the need for new antibiotic compounds, strategies for screening for new antibiotics, sources of novel synthetic and natural antibiotics, discovery phases of lead development and optimization, and candidate compound nominations into development. Beyond discovery , the handbook will cover all of the studies to prepare for IND submission: Phase I (safety and dose ranging), progression to Phase II (efficacy), and Phase III (capturing desired initial indications). This book walks the reader through all aspects of the process, which has never been done before in a single reference. With the rise of antibiotic resistance and the increasing view that a crisis may be looming in infectious diseases, there are strong signs of renewed emphasis in antibiotic research. The purpose of the handbook is to offer a detailed overview of all aspects of the problem posed by antibiotic discovery and development.

Author: World Health Organization
Publisher: World Health Organization
ISBN: 924009346X
Category : Medical
Languages : en
Pages : 72

View

Book Description

Author: Boyan B. Bonev
Publisher: John Wiley & Sons
ISBN: 1119558204
Category : Science
Languages : en
Pages : 288

View

Book Description
AN AUTHORITATIVE SURVEY OF CURRENT RESEARCH INTO CLINICALLY USEFUL CONVENTIONAL AND NONCONVENTIONAL ANTIBIOTIC THERAPEUTICS Pharmaceutically-active antibiotics revolutionized the treatment of infectious diseases, leading to decreased mortality and increased life expectancy. However, recent years have seen an alarming rise in the number and frequency of antibiotic-resistant "Superbugs." The Centers for Disease Control and Prevention (CDC) estimates that over two million antibiotic-resistant infections occur in the United States annually, resulting in approximately 23,000 deaths. Despite the danger to public health, a minimal number of new antibiotic drugs are currently in development or in clinical trials by major pharmaceutical companies. To prevent reverting back to the pre-antibiotic era—when diseases caused by parasites or infections were virtually untreatable and frequently resulted in death—new and innovative approaches are needed to combat the increasing resistance of pathogenic bacteria to antibiotics. Bacterial Resistance to Antibiotics – From Molecules to Man examines the current state and future direction of research into developing clinically-useful next-generation novel antibiotics. An internationally-recognized team of experts cover topics including glycopeptide antibiotic resistance, anti-tuberculosis agents, anti-virulence therapies, tetracyclines, the molecular and structural determinants of resistance, and more. Presents a multidisciplinary approach for the optimization of novel antibiotics for maximum potency, minimal toxicity, and appropriated degradability Highlights critical aspects that may relieve the problematic medical situation of antibiotic resistance Includes an overview of the genetic and molecular mechanisms of antibiotic resistance Addresses contemporary issues of global public health and longevity Includes full references, author remarks, and color illustrations, graphs, and charts Bacterial Resistance to Antibiotics – From Molecules to Man is a valuable source of up-to-date information for medical practitioners, researchers, academics, and professionals in public health, pharmaceuticals, microbiology, and related fields.

Author: National Research Council
Publisher: National Academies Press
ISBN: 0309298172
Category : Science
Languages : en
Pages : 82

View

Book Description
Technological Challenges in Antibiotic Discovery and Development is the summary of a workshop convened by the Chemical Sciences Roundtable in September 2013 to explore the current state of antibiotic discovery and examine the technology available to facilitate development. Through formal presentations and panel discussions, participants from academia, industry, federal research agencies discussed the technical challenges present and the incentives and disincentives industry faces in antibiotic development, and identified novel approaches to antibiotic discovery. Antibiotic resistance is a serious and growing problem in modern medicine and it is emerging as a pre-eminent public health threat. Each year in the United States alone, at least two million acquire serious infections with bacteria that are resistant to one or more antibiotics, and at least 23,000 people die annually as a direct result of these antibiotic-resistant infections. In addition to the toll on human life, antibiotic-resistant infections add considerable and avoidable costs to the already overburdened U.S. health care system. This report explores the challenges in overcoming antibiotic resistance, screening for new antibiotics, and delivering them to the sites of infection in the body. The report also discusses a path forward to develop the next generation of potent antimicrobial compounds capable of once again tilting the battle against microbial pathogens in favor of humans. Technological Challenges in Antibiotic Discovery and Development gives a broad view of the landscape of antibiotic development and the technological challenges and barriers to be overcome.

Author: Ramanan Laxminarayan
Publisher: Routledge
ISBN: 1136527605
Category : Medical
Languages : en
Pages : 193

View

Book Description
Our ability to treat common bacterial infections with antibiotics goes back only 65 years. However, the authors of this report make it clear that sustaining a supply of effective and affordable antibiotics cannot be without changes to the incentives facing patients, physicians, hospitals, insurers, and pharmaceutical manufacturers. In fact, increasing resistance to these drugs is already exacting a terrible price. Every day in the United States, approximately 172 men, women, and children die from infections caused by antibiotic-resistant bacteria in hospitals alone. Beyond those deaths, antibiotic resistance is costing billions of dollars through prolonged hospital stays and the need for doctors to resort to ever more costly drugs to use as substitute treatments. Extending the Cure presents the problem of antibiotic resistance as a conflict between individual decision makers and their short-term interest and the interest of society as a whole, in both present and future: The effort that doctors make to please each patient by prescribing a drug when it might not be properly indicated, poor monitoring of discharged patients to ensure that they do not transmit drug-resistant pathogens to other persons, excesses in the marketing of new antibiotics, and the broad overuse of antibiotics all contribute to the development and spread of antibiotic-resistant bacteria. The book explores a range of policy options that would encourage patients, health care providers, and managed care organizations to serve as more responsible stewards of existing antibiotics as well as proposals that would give pharmaceutical firms greater incentives to develop new antibiotics and avoid overselling. If the problem continues unaddressed, antibiotic resistance has the potential to derail the health care system and return us to a world where people of all ages routinely die from simple infections. As a basis for future research and a spur to a critically important dialogue, Extending the Cure is a fundamental first step in addressing this public health crisis. The Extending the Cure project is funded in part by the Robert Wood Johnson Foundation through its Pioneer Portfolio.

Author: Iqbal Ahmad
Publisher: John Wiley & Sons
ISBN: 3527622942
Category : Science
Languages : en
Pages : 322

View

Book Description
Combating bacterial infections calls for a multidisciplinary approach and this is what is on offer here. Written by an experienced international team of researchers from various fields ranging from biotechnology to traditional medicine, the book provides complete and comprehensive coverage of topics relevant to new antibacterial drugs. This ready reference and handbook adopts a novel approach, focusing on combating multi-drug resistance in bacteria by developing antibacterials with new target sites, using new advances in drug discovery as well as natural products. Divided into three sections, the first describes the problem of drug resistance and the need for new drugs, while the second treats recent trends and new classes of drugs, including relevant developments in transcriptomics and proteomics leading to new antimicrobial drug discovery, and a new generation of antibiotics and non-antibiotics. The third section on natural products discusses the antibacterial action of phytocompounds, plant extracts, essential oils and honey as well as the role of probiotics in bacterial infections. Invaluable to students of medicine, pharmaceutical sciences, phytomedicine and microbiology and all those wanting to know about the possibilities and limitations of new antibacterial drugs. Furthermore, its coverage of plants and other natural products makes this relevant to the pharmaceutical and herbal industries.

Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240097732
Category : Medical
Languages : en
Pages : 16

View

Book Description
The World Health Organization (WHO) policy brief, "Antibacterial pipeline trends and recommendations to enhance research and development" provides recommendations to strengthen R&D for antibacterials based on current trends in the antibacterial pipeline, as part of a comprehensive effort to address persistent global health challenge posed by antimicrobial resistance (AMR). This WHO policy brief is based on the latest WHO pipeline report “2023 Antibacterial agents in clinical and preclinical development: an overview and analysis” (IRIS link) and is intended to serve as a tool for drug developers, policymakers and funders of research and development (R&D) in AMR and basic AMR research. The goal of this WHO policy brief is to guide the implementation of strategies to respond to persistent R&D challenges and strengthen the antibacterial pipeline. It highlights the continued urgent need for innovative drugs to combat drug-resistant infections, particularly against priority pathogens identified in the 2024 WHO Bacterial Priority Pathogen List (IRIS link) and other crucial gaps in the pipeline including drugs to address serious bacterial infections in the populations most affected, such as vulnerable patient populations. The WHO policy brief emphasizes global coordination and collaboration to advance R&D for antibacterial agents.

Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240060243
Category : Medical
Languages : en
Pages : 48

View

Book Description